PHAZAR/RuxAza - A phase Ib study to assess the safety and tolerability of oral Ruxolitinib in combination with 5 azacitidine in patients with accelerated phase MPNs, MDS or AML after MPNs

  • Siddique, Shamyla (Co-Investigator)
  • Fox, Sonia (Co-Investigator)
  • Fenwick, Nicola (Co-Investigator)
  • Jackson, Aimee (Principal Investigator)

Project Details

Short titlePHAZAR/RuxAza - A phase Ib study to assess the safety and tolerability of oral Ruxolitinib in combination with 5 azacitidine in patients with accelerated phase MPNs, MDS or AML after MPNs
StatusActive
Effective start/end date1/04/14 → 31/12/24

Funding

  • NOVARTIS PHARMACEUTICALS UK LTD
  • CELGENE INTERNATIONAL SARL
  • BLOODWISE